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Reply to the Editor:
I appreciate the letter by Rosenfeldt and col-
leagues, and I fully agree that prevention of
vein graft disease is the first step to improve
vein graft longevity. In addition to using a
surgical no-touch technique, Souza and col-
leagues1 recently presented long-term data on
the superior performance of saphenous veins
that were harvested with their surrounding
tissue. The ischemic time of the harvested
vein and the type of storage medium play a
role too. Furthermore, we have to keep in
mind that the greater the target vessel diam-
eter the better the vein graft longevity.
Rosenfeldt and colleagues focus on the prob-
lem of dilation of the saphenous veins before
implantation, which inevitably leads to en-
dothelial injury (and stretch-induced apo-
ptosis of vascular cells). Their concept of
pharmacologic (instead of mechanical) dila-
tion of the saphenous veins in coronary artery
bypass grafting seems to be a rational con-
cept. However, single preventive or therapeu-
tic strategies against vein graft disease are
insufficient. Thus, a combination of mea-
surements seems worthwhile. A variety of
models of vein graft disease have taught us
pathologic features of vein graft disease.2
Nevertheless, only a couple of therapeutic
interventions (systemic pharmacotherapy)
have reached clinical practice (mainly as-
pirin and statins). Thus, an additional local
therapy of the vein graft might be an at-
tractive option to fulfill the armamentarium
of the cardiac surgeon against vein graft
degeneration (Figure 1).
Thomas Schachner, MD
Department of Cardiac Surgery
Innsbruck Medical University
Innsbruck, Austria
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To the Editor:
We appreciate Dr Chitwood’s insightful edi-
torial1 concerning our report on endoscopic
robotic mitral valve surgery.2 We disagree,
however, with his opinion concerning the
capability of the patient-side assistant in ro-
botic mitral valve surgery. Chitwood states
the “ideal robotic mitral” should be per-
formed completely robotically from the op-
erative console because “a port incision less
than 4 cm does not facilitate extracorporeal
knot tying or other cardiac manipulations.” In
our clinical experience we have not found
this observation to be true. As we reported,
the patient-side assistant using shafted instru-
ments plays an important role in our endo-
scopic robotic technique, both enhancing
valve exposure and facilitating valve repair.
In fact, extracorporeal suture tying by the
patient-side assistant using a closed loop knot
pusher has become our routine because it is
faster and more consistent in our experience
than robotic tying by the console surgeon.
How could 2 clinically experienced robotic
mitral surgery teams have such a different
perception of the capability of the patient-
side assistant? We believe the answer relates
to a critical difference in the port incision
locations between our respective robotic mi-
tral techniques. Chitwood uses a single infra-
mammary fold incision for both endoscope
insertion and patient-side assistant access.3
By using straight, shafted, handheld instru-
ments passed immediately adjacent and
nearly parallel to a 30-degree up endoscope,
we believe conflicts are inherent for Chit-
wood’s assistant attempting to reach valvular
structures. We use separate ports for the en-
doscope and the assistant’s access and locate
these ports substantially more laterally on the
chest wall than Chitwood’s technique. By
separating these 2 ports and moving them
laterally we exploit the natural curvature of
the thoracic cage to compensate for the dif-
ference between the angled endoscope and
the assistant’s straight instruments. This ori-
entation minimizes instrument conflicts and
facilitates the assistant’s ability to reach the
valvular structures directly. In our initial ex-
perience this assistant access port was
slightly less than 4 cm, but now with the
newer robotic system this port incision has
been reduced to 2 cm (Figure 1). Our patient-
side assistant continues to play an active role
in valve repair through this smaller port.
From the standpoint of patient care, it has
been the quality of the knots that has been
clinically relevant, not which member of the
surgical team tied them. Although the surgi-
cal technique we describe may or may not be
“real endoscopic cardiac surgery,” it has per-
mitted us to achieve a higher mitral valve
repair rate with minimal invasion.
Douglas A. Murphy, MD
Jeffrey S. Miller, MD
David A. Langford, MD
Department of Cardiothoracic Surgery
Saint Joseph’s Hospital of Atlanta
Atlanta, Ga
Figure 1. Strategies to fight vein graft
disease.
Figure 1. Endoscopic robotic ports. S, Pa-
tient-side assistant’s port; R, right robotic
instrument arm; L, left robotic instrument
arm; E, robotic endoscope; A, robotic atrial
retractor arm.
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Reply to the Editor:
I appreciate Murphy and colleagues’ letter
to the editor,1 discussing the differences in
our robotic surgical methods.2,3 To be sure,
both his group and ours have attained ex-
cellent results with robotic mitral valve re-
pairs. He is correct in that we use different
sites for working-port and camera inci-
sions, and this difference definitely facili-
tates hand-tying of intracardiac sutures by
the patient-side surgeon. Nevertheless, we
are traveling toward a totally endoscopic
mitral operation, and the necessity for pa-
tient-side intracardiac assistance to perform
the operation requires 2 experienced sur-
geons. Thus, if we are to become asymp-
totic to “real endoscopic cardiac mitral sur-
gery,” experienced surgeons, such as Dr
Murphy, must strive to achieve repairs us-
ing all robotic techniques, which would
lessen the need for an experienced patient-
side surgeon. Are these points moot or are
they important? When good surgeons dis-
agree, each becomes more circumspect and
these dialogs help us advance our specialty—
“our destiny.” To this end, I appreciate and
respect both Dr Murphy and colleagues’ let-
ter and opinions.
W. Randolph Chitwood, Jr, MD, FACS, FRCS
Division of Cardiothoracic and
Vascular Surgery
East Carolina University
Greenville, NC
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Which cell is transferred hepatocyte
growth factor gene?
To the Editor:
I read with interest the article by Shi and
associates,1 titled “Nonviral Gene Transfer
of Hepatocyte Growth Factor Attenuates
Neurologic Injury After Spinal Cord Isch-
emia in Rabbits.” It is already known that
hepatocyte growth factor (HGF) functions
as a powerful angiogenic factor, as well as
a potent neurotrophic factor,2 and HGF is
not expressed in the spinal cord in the early
phase after the ischemia.3 Thus I agree that
gene transfer of HGF could induce toler-
ance against a severe spinal cord ischemic
insult. Furthermore, intrathecal injection of
HGF gene is less invasive than viral injec-
tion to the spinal cord. However, I have one
question. The authors have not demon-
strated that HGF was induced in any cells.
Johnson and associates4 demonstrated that
flunarizine has a protective effect on neu-
rologic recovery after spinal cord ischemia,
and the mechanism of protection involves
inhibition of calcium accumulation rather
than a direct effect on vascular smooth
muscle using spinal cord blood flow mea-
surements. Furthermore, Hayashi and asso-
ciates5 demonstrated that prevention of de-
layed CA1 neuronal death after cerebral
ischemia in the gerbil by subarachnoid
HGF gene transfer is due to the inhibition
of apoptosis through the blockade of Bax
translocation from the cytoplasm to the nu-
cleus. These results suggest that HGF gene
into intrathecal injection may have a protec-
tive effect against neuronal apoptotic cascade
rather than angiogenic effect. Therefore, to
elucidate the mechanism of neuronal protec-
tion, the authors should demonstrate tempo-
ral profiles of HGF in histochemical study or
in in situ hybridization study.
Masahiro Sakurai, MD, PhD
Department of Cardiovascular Surgery
National Hospital Organization Sendai
Medical Center
Sendai, Japan
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Reply to the Editor:
My colleagues and I thank Dr Sakurai for
his insightful comments on our recently
published article. Tolerance induced by
gene transfer of hepatocyte growth factor
(HGF) against ischemia insults has been
well described in the literature, including
our study,1,2 in which the question about
which cell was the target for gene transfer
and then expressed with HGF was eclipsed
by the emphasis on the assessment of neu-
roprotective effects and its possible mech-
anisms. We appreciate that the question
raised by Dr Sakurai is very important.
Human HGF was detected in the pia matter
and parenchyma when HGF was trans-
ferred by intracisternal injection using the
same vector. It seemed that multiple cells
might secrete HGF, including neurons.3 Of
cause, only further study is the best answer.
Spinal cord ischemia can induce two kinds
of motor neuron death: necrosis and apo-
ptosis. It is thought that the delayed and
selective motor neuron death, which occurs
a few days after a relatively short period of
spinal cord ischemia (less than 20 minutes
in the rabbit model) accompanied by de-
layed paraplegia, is due to neuronal apo-
ptosis, whereas necrosis usually occurs af-
ter acute ischemia.4 In the current study,
rabbits were subjected to a 30-minute pe-
riod of ischemia, and most animals were
completely paraplegic 1 day after transient
ischemia. The previous work of our depart-
ment showed that a 30-minute period of
ischemia induced almost a total loss of
motor neurons 2 days after reperfusion.5
Therefore, the motor neuron damage in the
current study was mediated mainly through
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